Skip to main content

Grafting vs Intraoperative Mitomycin C for Preventing Pterygium Recurrence: A Randomized Clinical Trial

In brief

Conjunctival graft cut pterygium recurrence to 5%, versus 14% with mitomycin

In a randomized trial of 750 patients having primary pterygium surgery, recurrence at one year was 5.0% with a conjunctival graft, 13.7% with mitomycin C, and 22.9% with an amniotic membrane transplant. Serious complications were not linked to any procedure, but recurrence prevention is only one factor in choosing surgery.

Journal
JAMA ophthalmology (Q1)
Published
19 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Wen-Yan Peng, Wen-Rui Deng, Li Luo, Ling Jin, Hai Liu, Hai-Feng Zhu, et al.
PMID
43056092
DOI
10.1001/jamaophthalmol.2026.5279

Why clinicians should know about it

  • Picked for Ophthalmology (top studies of the week, 22 November 2026): Randomized comparison of pterygium surgical recurrence prevention

Abstract

IMPORTANCE: Postoperative recurrence remains a major challenge after primary pterygium surgery, and whether grafting approaches are more effective than intraoperative mitomycin C (MMC) in reducing recurrence remains uncertain. OBJECTIVE: To determine whether grafting with conjunctival autograft (CAG) or amniotic membrane transplant (AMT) is superior to MMC in preventing 1-year recurrence after primary pterygium excision. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label randomized clinical trial with masked outcome assessment with 12-month follow-up was conducted at 5 tertiary hospitals in China. Enrollment and follow-up occurred between January 2016 and December 2020, and data were analyzed from September 2025 through January 2026. Patients aged 18 to 80 years with primary pterygium were enrolled and randomly assigned 1:1:1 to AMT (n = 249), MMC (n = 248), or CAG (n = 253). INTERVENTIONS: Standardized pterygium excision with conjunctival excision extending radially 4 mm from the limbus, combined with AMT, MMC, or CAG. MAIN OUTCOMES AND MEASURES: The primary outcome was 12-month postoperative recurrence. Secondary outcomes included best-corrected visual acuity, epithelial healing time, and conjunctival congestion scores. RESULTS: Of 750 randomized participants (mean [SD] age, 57.2 [10.5] years; 487 women [64.9%]), 681 (90.8%) completed follow-up. Recurrence in the intention-to-treat analysis was 57 participants of 249 with AMT (22.9%), 34 of 248 with MMC (13.7%), and 13 of 253 with CAG (5.0%). Risk differences were 9.2 percentage points for AMT vs MMC (98.33% CI, 0.6-17.9; P = .01), 17.9 for AMT vs CAG (98.33% CI, 10.5-25.4; P < .001), and 8.7 for MMC vs CAG (98.33% CI, 2.2-15.2; P = .001). Risk ratios were 1.69 (98.33% CI, 0.99-2.91; P = .02), 4.62 (98.33% CI, 2.14-9.97; P < .001), and 2.73 (98.33% CI, 1.20-6.20; P = .004), respectively. Complete-case analyses yielded similar results. Adverse events occurred in 18 of 249 AMT participants (7.2%), 28 of 248 MMC participants (11.3%), and 16 of 253 CAG participants (6.3%), with no intervention-related serious adverse events. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, among patients undergoing primary pterygium excision, recurrence was lowest with CAG, intermediate with MMC, and highest with AMT. The moderate magnitude of the between-procedure differences makes recurrence prevention an important-but not exclusive-determinant of surgical choice and may inform individualized surgical management. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02102776.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.